Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040).
Saved in:
| Title: | Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040). |
|---|---|
| Authors: | Sangro B; Liver Unit, Clinica Universidad de Navarra-IDISNA and CIBEREHD, Pamplona, Spain., Yau T; University of Hong Kong, Hong Kong Special Administrative Region, Pokfulam, China., El-Khoueiry AB; Keck School of Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, California, USA., Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan., Shen Y; Bristol Myers Squibb, Princeton, New Jersey, USA., Tschaika M; Bristol Myers Squibb, Princeton, New Jersey, USA., Roy A; Bristol Myers Squibb, Princeton, New Jersey, USA., Feng Y; Bristol Myers Squibb, Princeton, New Jersey, USA., Gao L; Bristol Myers Squibb, Princeton, New Jersey, USA., Aras U; Bristol Myers Squibb, Princeton, New Jersey, USA. |
| Source: | Clinical and translational science [Clin Transl Sci] 2023 Aug; Vol. 16 (8), pp. 1445-1457. Date of Electronic Publication: 2023 May 30. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
